

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/CA04/002084

International filing date: 06 December 2004 (06.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/568,225  
Filing date: 06 May 2004 (06.05.2004)

Date of receipt at the International Bureau: 11 February 2005 (11.02.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

06 JANUARY 2005 06.01.05

PA 1260258



# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office


December 15, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/568,225

FILING DATE: May 06, 2004

By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS



  
N. WOODSON  
Certifying Officer

Please type a plus sign (+) inside this box ☐

PTO/SB/18 (5-03)  
Approved for use through 04/30/2003. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

17858 U.S. PTO  
60/568225



050604

### INVENTOR(S)

Given Name (first and middle (if any))	Family Name or Surname	Residence (City and either State or Foreign Country)
Jody	Berry	Winnipeg Manitoba Canada
Steve	Jones	Winnipeg Manitoba Canada
Xin	Yong Yuan	Winnipeg Manitoba Canada
Mike	Gubbins	Winnipeg Manitoba Canada

☒ Additional inventors are being named on the \_\_\_\_\_ separately numbered sheets attached hereto

### TITLE OF THE INVENTION (280 characters max)

ANTI-SARS MONOCLONAL ANTIBODIES

Direct all correspondence to:

### CORRESPONDENCE ADDRESS

☒ Customer Number **23529**  
OR  
Type Customer Number here

Place Customer Number  
Bar Code Label here

☒ Firm or  
Individual Name **ADE & COMPANY**

Address **1700-360 Main Street**

Address

City **Winnipeg** State **Manitoba** ZIP **R3C 3Z3**

Country **Canada** Telephone **204-947-1429** Fax **204-942-5723**

### ENCLOSED APPLICATION PARTS (check all that apply)

☒ Specification Number of Pages

**26**

☐ CD(s), Number

☒ Drawing(s) Number of Sheets

**13**

☐ Other (specify)

☐ Application Data Sheet. See 37 CFR 1.76

### METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)

☒ A check or money order is enclosed to cover the filing fees

☐ The Director is hereby authorized to charge filing  
fees or credit any overpayment to Deposit Account Number

☐ Payment by credit card. Form PTO-2038 is attached.

FILING FEE  
AMOUNT (\$)

**\$160.00**

The invention was made by an agency of the United States Government or under a contract with an agency of the  
United States Government.

☒ No.

☐ Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted,

SIGNATURE

*Michael R. Williams*

TYPED or PRINTED NAME **Michael R. Williams**

TELEPHONE

**204-957-8364**

Date

**05/05/04**

REGISTRATION NO.

**45,333**

(if appropriate)

Docket Number:

**85084-872**

## USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

P19LARGE/REV05

**PROVISIONAL APPLICATION COVER SHEET**

*Additional Page*

PTO/SB/16 (8-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Docket Number	85084-872	Type a plus sign (+) inside this box →
INVENTOR(S)/APPLICANT(S)				
Given Name (first and middle [if any])	Family or Surname	Residence (City and either State or Foreign Country)		
Anton	Andonov	Winnipeg Manitoba Canada		
Hana	Weingartl	Winnipeg Manitoba Canada		
Mike	Drebot	Winnipeg Manitoba Canada		
Frank	Plummer	Winnipeg Manitoba Canada		

Number \_\_\_\_\_ of \_\_\_\_\_

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

## ANTI-SARS MONOCLONAL ANTIBODIES

### FIELD OF THE INVENTION

5 The present invention relates generally to the field of therapeutic or medical treatments and methods of diagnosis and detection. More specifically, the present invention relates to a plurality of anti-SARS monoclonal antibodies.

### BACKGROUND OF THE INVENTION

10 The SARS-Coronavirus (SARS-HCoV) has been implicated as the causative agent of SARS (severe acute respiratory syndrome) in humans. This virus has caused multiple deaths in various affected countries throughout the world. The SARS coronavirus spike protein has only 30% identity at the amino acid level to the spike proteins of the previously characterised coronaviruses. Recently, the genome of SARS isolates implicated in the 2003 Toronto outbreak were sequenced in their  
15 entirety (Marco et al., 2003, Science 300: 1399-1404; Rota et al., 2003, Science 300: 1394-1399). The production of mAbs specific to this agent is critical for diagnostic development, vaccine research and studies of viral pathogenesis. Assays that detect the presence of virally encoded proteins or nucleic acids may be preferable for diagnosis of SARS infections as the development of serum antibodies is quite  
20 protracted (Li et al., 2003, N. Engl. J. Med. 349: 508-509).

Coronaviruses are enveloped, single stranded RNA viruses that replicate in the host cell cytoplasm [Fields, B.N., Knipe, D.M., Howley, P.M., and Griffin, D.E. (2001) Fields Virology (Lippincott Williams & Wilkins, Philadelphia, ed. 4)]. The coronaviruses form a single genus of the family Coronaviridae and the virions are  
25 large (80-160 nm in diameter), pleomorphic but generally spherical particles. Virions of most coronaviruses contain three major proteins: the phosphorylated nucleocapsid protein N; a small membrane-embedded glycoprotein (M); and a large club-shaped peplomer glycoprotein (S) which appears in EM micrographs as protruding spikes 20 nm in length. The M protein is synthesized on ribosomes bound to the endoplasmic  
30 reticulum and accumulates in the Golgi apparatus. The subcellular localization of M

protein to the Golgi is believed to determine the site of virus budding from the infected cell. The S protein mediates many of the biological properties of the virus, including attachment to cell receptors, penetration, and cell-fusion, and it is the major target for virus-neutralizing antibodies (Collins et al., 1982, *Virology* 61:1814-1820; Talbot et al., 1984 *Virology* 132: 250-260; Wege and Dorrier, 1984, *J. Gen. Virol.* 65: 217-227; Laude et al., 1986, *J. Gen. Virol.* 67: 119-130; Jimenez et al., 1986, *J. Virol.* 60: 131-139; Godet et al., 1994, *J. Virol.* 68: 8008-8016). A proportion of the S glycoprotein that is not incorporated into budding virions is transported to the plasma membrane of the cell where it remains bound to the cell surface (Gerna et al., 1982, *J. Gen. Virol.* 60: 385-390).

Coronaviruses infect a wide range of mammalian hosts to produce a variety of disease outcomes including respiratory disease, enteritis and encephalitis. Antigenic similarities between various coronaviruses have been demonstrated to reside in the S protein and have been used to study evolution of this virus family [Brian, D.A., Hogue, B., Lapps, W., Potts, B. and Kapke, P. (1983) *Proc. 4th Int. Symp. Neonatal Diarrhea* (S.D. Acres, Saskatoon, Canada ed.)]. For most coronaviruses causing enteric and respiratory diseases the pathophysiological events leading to clinical symptoms are due to the acute cytotoxic infection of the target cells. These infections can be limited by the local immune response resulting in the production of secretory antibodies specific for the S protein (Enjuanes et al., 1995, *Dev. Biol. Stand.* 84: 145-152). In contrast, many coronaviruses are maintained and spread in the population as inapparent and subclinical infections. The sequence of events leading to chronic disease is unknown but likely depends on the expression of viral genes, the functional impairment of host cells and the interaction with the host immune response.

There is a critical need to elucidate the immunologic basis for protection against SARS virus. The immunogenetics of antibody responses to protective epitopes is of particular importance and will lead to a clearer understanding of the nature of protective antibody responses to SARS. Lastly, the production of protective monoclonal antibodies may lead to the development of new recombinant therapeutic antibodies in order to provide rapid protection in SARS patients. In the present work

we describe the development of murine mAbs against the SARS HCoV involved in the Toronto SARS outbreak. The mAbs were analysed for pertinent immunochemical properties and for their ability to neutralize the SARS virus in vitro.

## 5 SUMMARY OF THE INVENTION

According to a first aspect of the invention, there is provided a SARS detecting monoclonal antibody selected from the group consisting of: F26G1, F26G2, F26G4, F26G5, F26G6, F26G8, F26G12, F26G13, F26G14, F26G16, F26G17, F26G3, F26G7, F26G9, F26G10, G26G18 and F26G19.

10 According to a second aspect of the invention, there is provided a SARS neutralizing monoclonal antibody selected from the group consisting of F26G3, F26G7, F26G9, F26G10, F26G18 and F26G19.

According to a third aspect of the invention, there is provided a kit comprising at least one monoclonal antibody selected from the group consisting of:  
15 F26G1, F26G2, F26G4, F26G5, F26G6, F26G8, F26G12, F26G13, F26G14, F26G16, F26G17, F26G3, F26G7, F26G9, F26G10, G26G18 and F26G19.

According to a fourth aspect of the invention, there is provided a pharmaceutical composition comprising a SARS neutralizing monoclonal antibody selected from the group consisting of F26G3, F26G7, F26G9, F26G10, F26G18,  
20 F26G19 and combinations thereof and a suitable excipient.

According to a fifth aspect of the invention, there is provided a method of preparing a chimeric antibody comprising:

introducing an expression vector which comprises a nucleic acid encoding a constant region domain of a human light or heavy chain and a nucleic acid  
25 encoding a light chain variable region selected from the group consisting of G1-light (SEQ ID No.1); G3-light (SEQ ID No.2); G6-light (SEQ ID No.3); G7-light (SEQ ID No.4); G8-light (SEQ ID No.5); G10-light (SEQ ID No.6); G15-light (SEQ ID No.7) and G18-light (SEQ ID No.8) or a heavy chain variable region selected from the group consisting of G1-heavy (SEQ ID No.9); G3-heavy (SEQ ID No.10); G6-heavy (SEQ ID  
30 No.11); G15-heavy (SEQ ID No.12) and G18-heavy (SEQ ID No.13) into a suitable

host cell;

growing the host cell under conditions promoting expression of the chimeric antibody; and

recovering the chimeric antibody.

5 According to a sixth aspect of the invention, there is provided a method of preparing a humanized antibody comprising:

providing a nucleic acid comprising a light chain variable region selected from the group consisting of G1-light (SEQ ID No.1); G3-light (SEQ ID No.2); G6-light (SEQ ID No.3); G7-light (SEQ ID No.4); G8-light (SEQ ID No.5); G10-light (SEQ ID  
10 No.6); G15-light (SEQ ID No.7) and G18-light (SEQ ID No.8) or a heavy chain variable region selected from the group consisting of G1-heavy (SEQ ID No.9); G3-heavy (SEQ ID No.10); G6-heavy (SEQ ID No.11); G15-heavy (SEQ ID No.12) and G18-heavy (SEQ ID No.13);

modifying said nucleic acid such that at least one but fewer than about  
15 30 of the amino acid residues of said variable region has been changed and/or deleted without disrupting antigen binding;

introducing said nucleic acid into a suitable host cell;

growing the host cell under conditions promoting expression of the humanized antibody; and

20 recovering the humanized antibody.

According to a seventh aspect of the invention, there is provided a pharmaceutical composition comprising a chimeric antibody as described above and a suitable carrier.

According to an eighth aspect of the invention, there is provided a  
25 pharmaceutical composition comprising a humanized antibody described above and a suitable carrier.

According to a ninth aspect of the invention, there is provided a method of preparing a vaccine comprising:

recovering from a preparation of live, attenuated or recombinant SARS  
30 virus, antigens recognized by one or more monoclonal antibodies selected from the



group consisting of F26G1, F26G2, F26G4, F26G5, F26G6, F26G8, F26G12, F26G13, F26G14, F26G16, F26G17, F26G3, F26G7, F26G9, F26G10, G26G18 and F26G19.

According to a tenth aspect of the invention, there is provided a nucleic acid molecule encoding a peptide comprising a light chain variable region selected from the group consisting of G1-light (SEQ ID No.1); G3-light (SEQ ID No.2); G6-light (SEQ ID No.3); G7-light (SEQ ID No.4); G8-light (SEQ ID No.5); G10-light (SEQ ID No.6); G15-light (SEQ ID No.7) and G18-light(SEQ ID No.8) or a heavy chain variable region selected from the group consisting of G1-heavy (SEQ ID No.9); G3-heavy (SEQ ID No.10); G6-heavy (SEQ ID No.11); G15-heavy (SEQ ID No.12) and G18-heavy (SEQ ID No.13).

#### BRIEF DESCRIPTION OF THE DRAWINGS

**Figure 1:** ELISA results of monoclonal antibody on whole inactivated SARS virus and BSA. Hybridoma supernatants were tested at a 1/4 dilution in PBS, 0.2% BSA on pre-blocked plates, coated with 18 ng per well of inactivated virus. Positive clones were identified as having positive binding (color) in wells which were at least 4 – fold higher than the background level reactivity on BSA. Antigen Legend: Black bars - native, purified SARS-HCoV ; White bars - BSA (bovine serum albumin).

**Figure 2:** Immunofluorescence staining of SARS HCoV-infected Vero cells with neutralizing and non-neutralizing SARS mAbs.; A. F26G6, non-neutralizing mAb specific for the spike protein. B. F26G3, neutralizing mAb. C. F26G7, neutralizing mAb. D. F26G9, neutralizing mAb. E. Irrelevant mAb, F25G1. F. Irrelevant mAb F25G1 in bright field.

**Figure 3.** Immunohistochemical analysis of binding of mAb F26G6 to (A) SARS infected but not (B) uninfected VERO cells.

**Figure 4.** Western immunoblot of monoclonal antibody on whole inactivated SARS virus and infected vero cell lysates. The positive and preimmune control sera were from the corresponding immune mouse and tested at 1/2000 dilution in TBS, 0.2% BSA . Lanes marked 1 were loaded with purified virus ; 2, with infected Vero cell

lysate.

Figure 5. This figure depicts Competition ELISA performed with F26G6 (anti-Spike) and F26G15 (anti-NP) mAbs on whole purified SARS virus as antigen. A dilution of each mAbs was chosen that would produce approximately 50% maximum OD reading. Human normal and convalescent SARS-infected sera was diluted as shown at the bottom of the graph and used as a competitor for binding to the SARS antigen. A goat antimurine secondary antibody conjugated to HRP (preabsorbed with multiple species including human to remove any potential crossreactivity) was used to detect murine mAb binding. Abrogation or reduction of the signal indicates the presence of human antibody to the same antigen/epitope in the human serum. This indicates that the individual was exposed or infected to the SARS corona virus. Our data also indicates that NP reactivity may be an earlier predictor of SARS infection as some sera inhibit NP binding mAb F26G15 but do not inhibit spike specific mAb F26G6. NHS=Normal human Sera tested at highest concentration 1/25 ; "S" are SARS patient convalescent sera.

Figure 6. Sequence data showing clones are unique and the id of the CDR regions that play a role in neutralization (see PDF files for improved resolution) The data shows that none of the VH or VL genes of the anti-SARS neutralizing or Western immunoblot positive mAbs are the same. This means that each hybridoma was derived from a unique B cell and target SARS using different proteins. (ie not the same clone picked several times)

Figure 7. SARS-specific monoclonal antibodies, Heavy chains (VH) amino acid sequences.

Figure 8. SARS-specific monoclonal antibodies, Light chains (VL) amino acid sequences.

Figure 9. SARS-specific monoclonal antibodies, Heavy chains (VH) nucleotide sequences.

Figure 10. SARS-specific monoclonal antibodies, Light chains (VL) nucleotide sequences.

## DESCRIPTION OF THE PREFERRED EMBODIMENTS

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or  
5 equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned hereunder are incorporated herein by reference.

## DEFINITIONS

10 As used herein, "neutralizing antibody" refers to an antibody, for example, a monoclonal antibody, capable of disrupting a formed viral particle or inhibiting formation of a viral particle or prevention of binding to or infection of mammalian cells with a viral particle.

As used herein, "diagnostic antibody" or "detection antibody" or  
15 "detecting antibody" refers to an antibody, for example, a monoclonal antibody, capable of detecting the presence of an antigenic target within a sample. As will be appreciated by one of skill in the art, such diagnostic antibodies preferably have high specificity for their antigenic target.

As used herein, "humanized antibodies" refer to antibodies with reduced  
20 immunogenicity in humans.

As used herein, "chimeric antibodies" refer to antibodies with reduced immunogenicity in humans built by genetically linking a non-human Variable region to human constant domains.

Described herein is the isolation, identification and characterization of a  
25 plurality of anti-SARS monoclonal antibodies.

As discussed herein, some of the monoclonal antibodies have been shown to have SARS neutralizing activity, meaning that said monoclonal antibodies, humanized or chimeric versions thereof or immunoreactive fragments thereof could be used as therapeutics for treating, preventing or ameliorating symptoms associated  
30 with SARS infection in patients in need of such treatment. The patients may be for

example human.

Also described herein are methods of producing anti-SARS mAbs, for example, humanized or chimeric anti-SARS mAbs. It is of note that these mAbs may be produced in a variety of systems, for example, germline cells or transgenic plants.

5 In these embodiments, an expression vector comprising a nucleic acid encoding an anti-SARS mAb or a humanized or chimeric version thereof or an immunoreactive fragment thereof is transformed into a suitable host and the host is grown under conditions promoting expression of the mAb which is then recovered. The mAbs may then be purified using means known in the art and used to develop pharmaceuticals,  
10 as discussed below.

As described herein, some of the monoclonal antibodies are useful for detection of SARS virus within biological samples for example, but by no means limited to, infected cells, directly on viral particle in infected cell lysates, in purified virus fractions, serum, whole blood, naso-pharyngeal swabs, stool, or bronchio-  
15 alveolar lavage. As will be appreciated by one of skill in the art, individual detection monoclonal antibodies or combinations thereof may be packaged in a kit along with instructions for use, as described below.

The SARS detection monoclonal antibodies may be selected from the group consisting of: F26G1, F26G2, F26G4, F26G5, F26G6, F26G8, F26G12,  
20 F26G13, F26G14, F26G16, F26G17, F26G3, F26G7, F26G9, F26G10, G26G18 and F26G19.

The SARS neutralizing monoclonal antibodies may be selected from the group consisting of F26G3, F26G7, F26G9, F26G10, F26G18 and F26G19.

As will be appreciated by one of skill in the art, the monoclonal  
25 antibodies may be used individually or in any combination thereof.

As will be appreciated by one of skill in the art, detection antibodies must show high specificity and avidity for their antigenic target. As such, showing that a monoclonal antibody reacts with the antigenic target derived from a highly purified or in vitro prepared sample does not guarantee that the antibody has sufficient  
30 specificity for use with biological sample. That is, the monoclonal antibody must have

sufficient specificity that it will not produce false positives or react with antigens from related, non-SARS coronaviridae.

Examples of suitable tests for determining utility as a diagnostic or as a neutralizing mAb include but are by no means limited to negative neutralization and/or negative detection of a non-SARS coronavirus, C-ELISA data showing competition of binding with the mouse mAbs that is being detected thereby showing that the mAbs can be used to show that an immune response to SARS has occurred in patient/animal sera, meaning that they were exposed/infected (abrogation of binding by human antibodies). Alternatively, biological material such as blood, mucus or stool with could be spiked with the virus and the monoclonal antibodies used to detect added virus in the sample, which would in turn determine limits of detection as well as other parameters of the monoclonal antibodies. Biological samples from experimentally infected animals could also be used to determine the utility of the mAbs at different stages of the infection cycle. Yet another method, although less desirable, would be testing of the patient material from the outbreak as this is scarce and hence valuable material.

In use, at least one of the detection antibodies is mixed with a biological sample under suitable conditions to promote binding of the at least one detection antibody with the antigenic target if the antigenic target is present in the biological sample. Binding of the detection antibody to an antigenic target within the sample is then detected using means known in the art, for example, by use of a labelled secondary antibody or other means discussed herein and/or known in the art.

As will be apparent to one of skill in the art, a combination of detection antibodies may be used. Furthermore, at least one of the detection antibodies or combinations thereof may be packaged in a kit for detecting SARS virus in biological samples. The kit may include instructions and additional reagents, for example, secondary antibodies, buffers, detection reagents and the like. Antibodies of the kit could be used for example in a capture ELISA wherein one or more mAb is coated onto a surface to catch and present SARS antigen from biological samples, then another prelabelled mAb is added to detect the presence of the antigen; as a control

for indirect ELISA wherein a surface is coated with SARS antigen and the presence of antibody binding to the antigen is detected; for immunofluorescence; or for competition ELISA wherein SARS antigen is coated on a surface, and the ability of human or other infected/exposed animal serum antibody to prevent binding of one or more of the mAbs to the SARS antigen is measured.

The neutralizing antibodies were previously shown to react with a conformational epitope of the native virus which is abrogated upon denaturation of the virus. However, as will be appreciated by one of skill in the art, this does not guarantee that the neutralizing antibodies will be effective in either preventing virus formation or disrupting intact virus particles *in vivo*, that is, that the neutralizing antibodies will have therapeutic activity.

For example Maruyama et al demonstrated *in vitro* neutralization using monoclonal antibodies to Ebola virus and Parren et al confirmed this observation in guinea pigs; however in non-human primates there was no protection afforded by the monoclonal antibody. Furthermore, Jones et al. conducted extensive studies to identify which monoclonal antibodies were protective against infection with the bacteria *Burkholderia pseudomallei*. Whilst the *in vitro* neutralization is an excellent screening assay, the definitive test for neutralization is the *in vivo* protection assay. (Maruyama et al., J Virol. 1999; 73(7):6024-30; Parren et al., J Virol. 2002; 76(12):6408-12; Jones et al., J Med Microbiol. 2002;51(12):1055-62).

It has also been shown in HIV that *in vitro* neutralizing antibodies may not protect against primary isolate *in vivo* (Poignard et al., J Virol. 2003 Jan;77(1):353-65). In addition, mAbs that recognize the same region (epitope) but in different ways may have different neutralization properties, that is, one may neutralize while another may not, clearly indicating that neutralization is entirely empirical and needs to be tested. (Parren et al., J Virol. 1998 Dec;72(12):10270-4).

In another embodiment of the invention, a nucleic acid sequence encoding the neutralizing antibody as described above is subjected to humanization techniques or converted into a chimeric human molecule for generating a variant neutralizing antibody which has reduced immunogenicity in humans. Humanization

techniques are well known in the art – see for example US Patent 6,309,636 and US Patent 6,407,213. Chimerics are also well known, see for example US Patent 6,461,824, US Patent 6,204,023, US Patent 6,020,153 and US Patent 6,120,767.

In one embodiment of the invention, chimeric antibodies are prepared  
5 by preparing an expression vector which comprises a nucleic acid encoding a constant region domain of a human light or heavy chain genetically linked to a nucleic acid encoding a light chain variable region selected from the group consisting of G1-light (SEQ ID No.1); G3-light (SEQ ID No.2); G6-light (SEQ ID No.3); G7-light (SEQ ID No.4); G8-light (SEQ ID No.5); G10-light (SEQ ID No.6); G15-light (SEQ ID No.7)  
10 and G18-light (SEQ ID No.8) or a heavy chain variable region selected from the group consisting of G1-heavy (SEQ ID No.9); G3-heavy (SEQ ID No.10); G6-heavy (SEQ ID No.11); G15-heavy (SEQ ID No.12) and G18-heavy (SEQ ID No.13). It is of note that all of these sequences are shown in Figure 6.

In another embodiment of the invention, there are provided recombinant  
15 anti-SARS antibodies comprising at least one modified variable region, said region selected from the group consisting of G1-light (SEQ ID No.1); G3-light (SEQ ID No.2); G6-light (SEQ ID No.3); G7-light (SEQ ID No.4); G8-light (SEQ ID No.5); G10-light (SEQ ID No.6); G15-light (SEQ ID No.7); G18-light (SEQ ID No.8); G1-heavy (SEQ ID No.9); G3-heavy (SEQ ID No.10); G6-heavy (SEQ ID No.11); G15-heavy (SEQ ID  
20 No.12) and G18-heavy (SEQ ID No.13) in which at least one but fewer than about 30 of the amino acid residues of said variable region has been changed or deleted without disrupting antigen binding. It is of note that all of these sequences are shown in Figure 6.

In yet other embodiments, immunoreactive fragments of any of the  
25 above-described monoclonal antibodies, chimeric antibodies or humanized antibodies are prepared using means known in the art, for example, by preparing nested deletions using enzymatic degradation or convenient restriction enzymes.

It is of note that in all embodiments describing preparation of humanized  
antibodies, chimeric antibodies or immunoreactive fragments of monoclonal  
30 antibodies, these antibodies are screened to ensure that antigen binding has not been

disrupted. This may be accomplished by any of a variety of means known in the art, but one convenient method would involve use of a phage display library.

The nucleotide sequence encoding the Variable regions of the light and heavy chains of antigen specific hybridomas represent the specificity of the antibody.

5 Specifically the most important regions are the CDRs (of the light and heavy chains): L1, L2, L3 and H1 H2 H3 respectively. It will be apparent to one of skill in the art that the most importance CDR domains are those that are most variable in nature and thus are recruited most specifically by a given antigen like SARS. These are L1 and H3. Residues in H3 and other CDR comprise the paratope which interacts with the  
10 epitope on the pathogen. Amino acid residues in H3 have have been shown to directly interact/bind to residues of the epitope in crystal structure determinations. (Bossart-Whitaker et al., J Mol Biol. 1995 Nov 3;253(4):559-75; Chavali et al., Structure (Camb). 2003 Jul;11(7):875-85; Afonin et al., Protein Sci. 2001 Aug;10(8):1514-21; Karpusas et al., J Mol Biol. 2003 Apr 11;327(5):1031-41; Krykbaev et al., J Biol Chem.  
15 2001 Mar 16;276(11):8149-58. Epub 2000 Nov 01; Beiboer et al., J Mol Biol. 2000 Feb 25;296(3):833-49; Haruyama et al., Biol Pharm Bull. 2002 Dec;25(12):1537-45).

It is of note that as discussed herein, the above-described neutralizing antibody or humanized variant thereof may be formulated into a pharmaceutical treatment for providing passive immunity for individuals suspected of or at risk of  
20 SARS infection comprising a therapeutically effective amount of said antibody. The pharmaceutical preparation may include a suitable excipient or carrier. See, for example, Remington: The Science and Practice of Pharmacy, 1995, Gennaro ed. As will be apparent to one knowledgeable in the art, the total dosage will vary according to the weight, health and circumstances of the individual as well as the efficacy of the  
25 antibody.

In another embodiment of the invention, a vaccine is prepared by recovering from a preparation of live, attenuated or recombinant SARS virus, antigens recognized by one or more monoclonal antibodies selected from the group consisting of F26G1, F26G2, F26G4, F26G5, F26G6, F26G8, F26G12, F26G13, F26G14,  
30 F26G16, F26G17, F26G3, F26G7, F26G9, F26G10, G26G18 and F26G19.



The invention will now be described according to examples; however, the invention is not limited to or by the examples.

*Immunization and Virus Antigen Preparation:*

For immunizations 5-6 week old female BALB/C mice were used (Charles River). The mice were injected subcutaneously (S.C.) with 50-ug of beta-propiolactone-inactivated SARS-coronavirus (Tor-3 strain) with an equal part of Complete Freund's Adjuvant [CFA, H37 Ra; Difco], on day 1. The virus had been expanded after plaque purification in Vero-6 cell monolayers and partially purified through a sucrose cushion. Highly purified SARS-coronavirus (Tor-3) was prepared the same as above except that the viral particles were further purified using gradient centrifugation. (Highly purified SARS CoV was prepared as follows briefly, 500 ml of supernatant from SARS CoV infected Vero-6 cells was concentrated first on top of a cushion of iodixanol in a SW32 rotor (Beckman). Subsequently, the virus was mixed to form a suspension of 20% iodixanol and centrifuged in a NVT 90 rotor (Beckman) for 3.5 hours at 400,000g. Fractions were collected from the bottom of the self-generated gradient, tested by Western immunoblot with convalescent patient serum, and the SARS CoV positive fractions were pooled and dialysed against PBS. The dialysed virus preparation was further concentrated by ultracentrifugation for 1.5 hours at 150,000g. On day 30 the mice received 50 µg of purified SARS virus antigen S.C. in Incomplete Freund's Adjuvant (IFA) in a total volume of 100 µl. On days 48 and 63, the mice received 5 µg of the same antigen in a total volume of 100 µl S.C. with IFA. Mice received a final booster injection with 5 µg of purified SARS virus in 200 µl PBS to the intra-peritoneal cavity 3 days prior to hybridoma fusion. Mice were euthanised by anaesthesia overdose and exsanguinated by cardiac puncture. The spleens were subsequently excised under aseptic conditions.

*Preparation of Infected Cell lysate*

Infected Vero cells were scraped off of 162 cm<sup>2</sup> tissue culture flasks (Corning) and centrifuged for clarification. A borate saline mixture (0.05 M boric acid, 0.12 M, NaCl, 0.024 M NaOH) was used to wash the cell pellet twice and the pellet was

resuspended in 2 ml borate saline + 1 % triton x-100 for each T162 flask. The pellet was kept at 4°C using a water bath and sonicated for ten minutes at 50% power. The debris was pelleted via centrifugation at 10,000 X g for ten minutes and the supernatant collected and stored at -20°C in aliquots for later use.

5

*Generation of mAbs:*

Immunization of mice, removal of spleens, preparation of spleen and myeloma cells, and the fusion for hybridoma production were performed according to NCFAD standard operating procedures under IS017025. Ampules of the myeloma cell line  
10 P3X63Ag8.653 (ATCC) were thawed one week prior to fusion and grown in BD Cell Mab Quantum yield media in the presence of 8-Azaguanine (Sigma). Cells were in log-phase growth at the time of fusion. Hybridoma fusion was performed essentially as originally described (Kohler and Milstein, 1975, Nature 256: 495-497) with the following modifications. Briefly, spleens were harvested 3 days after a final boost and  
15 the splenocytes were prepared by splenic perfusion as follows. A 10 cc syringe with a 21 gauge sterile disposable needle was used to perforate the spleens under aseptic conditions. The spleen cells were perfused out of the spleen with injections of serum free BD cell Mab Quantum Yield medium (BD-Pharmingen). Two identically immunized mouse spleens were used to produce these hybridoma clones. The fusion  
20 was performed using the P3X63Ag8.653 myeloma line in log phase growth. The PEG1500, 1 ml, (Roche) was added drop-wise over one minute while gently tapping the tube containing the thoroughly washed myeloma-splenocyte pellet. The PEG was slowly diluted out over three minutes with serum free BD-Cell Mab Quantum Yield media (BD-Pharmingen). The cells were resuspended and mixed into 90 ml of  
25 Clonacell Medium D (HAT) media (Stemcell, Vancouver) containing 5 ml HCF, and plated out according to the manufacturers instructions. The plates were kept in a 37°C incubator under 5% CO<sub>2</sub> overlay for about 10-18 days in humidified chambers. Visible colonies were picked from the plates after about 2 weeks growth and placed into 96 well plates containing 150-200 µl of complete hybridoma medium (BD-Quantum Yield)  
30 with 1 X HT (Sigma), 4% Hybridoma cloning factor (Igen) and 10% FBS (Wisent).

Supernatants were screened 4 days later via ELISA on purified virus as antigen. Isotyping was performed using a commercial dipstick test (Roche) according to the manufacturer's instructions. Hybridoma culture supernatants were concentrated 5-10 fold using stirred cell nitrogen concentrators (Amicon) with a 30 kilodalton cutoff membrane (Millipore).

### *Immunoassays*

#### *Enzyme linked immunosorbent assay*

Tissue culture supernatants were assayed for binding to purified SARS coronavirus in an ELISA assay when the cultured cells were confluent in the culture plates. The Costar 3690 96-well  $\frac{1}{2}$  well ELISA plates (Corning) were coated with either Bovine serum albumin or purified SARS-coronavirus (18 - 37 ng/well) in PBS overnight at 4°C and then blocked with 0.4% BSA in PBS, for 2 hours at 37°C. The supernatant (30  $\mu$ l/well) was incubated neat for 1 hour at 37°C. The ELISA plates were washed ten times with dH<sub>2</sub>O and patted dry on a paper towel. A pan-goat anti-mouse IgG-HRP antibody (Southern Biotechnology Associates) was diluted to 1:2000 in 0.2% BSA in PBS, applied to the ELISA plates for 45 minutes at 37°C, and then washed as described above. Positive binding was detected with commercial ABTS used according to the manufacturers instructions (Roche). The OD was read at 405nm at 15 and 60 minute intervals after addition of the developing reagent. Mouse immune and preimmune sera was diluted to 1:2000 in 1.5 ml Eppendorf™ tubes (Falcon) in 2%-BSA PBS for use as controls.

#### *Western Immunoblots*

Whole virions or SARS-infected Vero cells at a total protein concentration of 1  $\mu$ g per lane were loaded in criterion pre-cast gels (BIO-RAD) and electrophoresed at 200 V for 30 minutes. The proteins were transferred to Immobilon nylon membranes (Millipore) for 2 hours at room temperature at 100 volts, or at 27 volts overnight at 4°C. Blots were blocked in 3% BSA-TBS, rinsed three times with TBS, and reacted with monoclonal antibody overnight at 4°C. The antibody supernatants were reacted

neat and concentrated supernatants were diluted 1:50 in 0.2% BSA-PBS. Blots were washed three times with TBS-tween-20 (0.05%) for five minutes before being incubated with secondary antibody (same as above) at 1:1000 in TBS, 0.2% BSA for 1 hour. The blots were washed as above and developed using DAB (Pierce) insoluble substrate.

#### *Immunofluorescence Staining of Vero cells infected with SARS-coronavirus*

Monolayers of EARS-infected Vero cells were stained as follows. Glass slides were coated with infected Vero cell monolayers and fixed with acetone. The slides were irradiated with 20 kilogreys from a cobalt gamma irradiator, removed from biocontainment, and then stored at -80°C. Dilutions of antibodies and test sera were made initially in 96 well plates (Falcon). Samples were allowed to incubate for 45 minutes in a 37°C incubator, and were washed with distilled water. Fluorescein labelled secondary antibodies (Sigma) diluted in PBS were added to the slides and incubated for 45 minutes at 37°C, washed as above, and air dried. Slides were coated with mounting medium and stored at 4°C until examined.

#### *Virus Neutralization*

##### *Plaque reduction virus neutralization assay (NML)*

A standard plaque reduction neutralization test was performed as previously described (Godet et al., 1994, J. Virol. 68: 8008-8016). Briefly, mixtures of pre-titred (100 PFUs) SARS coronavirus and serial 2-fold dilutions of hybridoma supernatant were incubated at 37°C for 1 hr and added to six well plates containing Vero cell monolayers. After a 37°C incubation for 1 hr, a nutrient-agar overlay was added and the plates placed in a CO<sub>2</sub> incubator for approximately 3 days. A second overlay was then added which contained neutral red as a vital stain. Plates were then checked periodically over the next few days for plaque formation. The highest dilution tested that produced a plaque reduction of at least 90% was defined as the titration end point.

*Cytopathic effect (CPE) reduction virus neutralization assay(NCFAD)*

The ELISA positive monoclonal antibodies were screened for cross-neutralization with other coronaviruses using microtiter format CPE reduction assay: concentrated monoclonal antibodies (hybridoma supernatants) were diluted 1:20 in  
5 cell culture medium and incubated with 100 TCID<sub>50</sub> of either SARS HCoV (Tor-3), or transmissible gastroenteritis virus (TGEV, Diamond strain; kindly provided by Dr. Susy Carman, LSD, University of Guelph) for 1 hr at 37°C. The virus-antibody mix was then transferred onto cell monolayers in 96-well plates (Costar, Corning, NY). Vero V-76 cells were used for the SARS WCoV, ST cells for the TGEV. The plates were  
10 incubated until CPE developed in virus back titration controls.

**Results and Discussion:**

*Development of mAbs to the SARS-virus*

We developed a panel of mAbs to the SARS HCoV. ELISA screening on  
15 purified SARS coronavirus identified a panel of 17 IgG/K type mAbs (Figure 1a, table 1). The general binding reactivity of these mAbs is decreased on heat denatured purified virus preparations indicating destruction of epitopes. There is a similar decrease in binding by many of these mAbs when tested on SARS-HCoV infected vero cell lysates as antigen. Heat denaturation had little effect on the binding of mAb  
20 F26G16 which also maintains a high OD on infected lysates. This mAb does however show higher background on the irrelevant antigen bovine serum albumin (BSA) (figure 1a) and has inconsistent reactivity in immunoblots with heat denatured viral lysate (table 1). Immunoblot methods are less sensitive than ELISA especially when using the lower quality infected cell lysate as antigen. Unfortunately preparation of highly  
25 purified viral antigen requires enormous efforts under containment which emphasizes the need for a quality recombinant antigen assay.

Western immunoblot analysis identified mAbs to the SARS spike protein. A total of five mAbs react with the SARS-spike protein in Western immunoblots, using the whole purified virus or virus infected cell lysate (Figure 1b). The antigen identity of  
30 the remaining 11 Western immunoblot negative mAbs could not be determined which

suggests that these mAbs target conformational epitopes that are destroyed in the Western blot sample preparation and membrane transfer process. These data led us to test for biological activity in virus neutralization assays.

#### 5 *Immunochemical and Biological Characterization of binding*

Neutralizing antibodies to the SARS virus recognize epitopes via interaction with both conformational and linear epitopes. We identified mAbs that neutralize in vitro cell culture infectivity of the SARS-virus. Concentrated culture supernatants from four of the eleven Western immunoblot negative (conformational) mAbs were significantly neutralizing compared to irrelevant isotype-matched concentrated mAbs to other antigens (Table 1). SARS virus infectivity was neutralized with mAbs F26G3, G7, G9, G10, G18 and G19. No cross-neutralization was observed for the animal coronavirus TGEV. The remaining mAbs in our panel showed no decrease in virus growth. This result reveals that we have developed mAbs specific for epitopes on the SARS coronavirus.

Immunoblot analysis reveals a spectrum of conformational requirements for binding. We examined the effects of different denaturing treatments on binding activity of a subset of neutralizing and some non-neutralizing mAbs using immunodot blot assays on infected lysates compared to uninfected lysates. A series of conditions were tested including exposure to heat, detergent, a reducing agent, and combinations thereof. The Immunodotblot reactivities of this panel of mAbs reveals important immunochemical requirements for their respective epitopes, and are summarized in table 1. In general the conformational requirements of the neutralizing antibodies are higher than the non-neutralizing and they are less tolerant of denaturation of the epitopes. None of the mAbs react with mock-infected lysates as assayed in Immunodotblots. This suggests that the majority of the neutralizing mAbs likely target surface exposed protein epitopes on the native viral particle, which has been identified as spike protein via Western analysis for mAbs F26G18 and F26G19. This is consistent with binding data observed in ELISA on heat denatured virus infected lysate compared to native infected lysate. In this case, regardless of Western

reactivity, the non-neutralizing clones retain more ability to bind to heat denatured antigens compared to neutralizing mAbs (lower mean percent reduction in OD per group  $p < 0.001$ , students T test). There are exceptions, however, in that it is difficult to use traditional classifications to describe the binding properties of these mAbs as being conformational or linear according to biological activity. Interestingly, clone F26G18 binds to spike protein in Western blot and neutralizes the SARS virus and thus the binding of F26G6 cannot be termed strictly conformational in nature. This is in contrast to neutralizing mAbs produced against other enveloped viruses (Zwick et al., 2001, J. Virol. 75: 6692-6699; Wilson et al., 2000, Science 287: 1664-1666) that require the antigen to have native conformation for binding. It will be important to verify, under optimized conditions (Opstelten et al., 1995, J. Cell Biol. 131: 339-349) the use of viral lysates designed for maximal recovery of coronavirus proteins and to this end the production of high quality recombinant protein antigens will provide useful insights.

SARS-virus reactivity was confirmed for the four Western immunoblot negative, virus neutralizing mAbs (F26G3, G7, G9, G10) using an immunofluorescence assay. In order to independently confirm recognition of native SARS antigens we tested these mAbs via immunofluorescence relative to a non-neutralizing mAb F26G6, which we know recognizes Spike protein in immunohistochemical staining of infected Vero cells. The neutralizing mAbs F26G3, G7, G9, and G10 specifically recognize SARS-HCoV infected but not uninfected Vero cells in immunofluorescence (Fig. 2). Irrelevant, isotype matched mAbs, produced in an identical fashion, do not react with SARS-virus infected Vero cells. These data are consistent with the appearance of coronavirus antigens on the surface of the infected cell during replication (Talbot et al., 1984, Virology 132: 250-260) although the fixation process may allow for reactivity of these mAbs with internal antigens as well. Collectively, these data demonstrate that these mAbs will be useful for developing antigen detection systems for diagnostics.

### *Conclusions*

Linear epitopes on the spike protein and conformational epitopes on as of yet

unknown antigen(s) provide neutralizing targets on the SARS virus. These data clearly show that the spike protein is a putative protective antigen, as it is the target of neutralizing mAbs F26G18 and G19. Moreover, these mAbs could be used to identify protective epitopes for vaccine formulations (Enjuanes et al., 1995, Dev. Biol. Stand.

5 84: 145-152). Studies are underway to determine the identity of the additional unknown antigen(s) recognized by the other neutralizing mAbs with more conformational epitopes. Molecular studies have revealed that the RT PCR amplified V-genes of the hybridoma clones that express these neutralizing mAbs contain distinct sequences. Therefore, the hybridomas expressing the neutralizing mAbs were  
10 derived from independently rearranged and clonally selected B cells in vivo, and are not derived from the same clone. This is the first description of SARS-HCoV specific and neutralizing mAbs and these antibodies should prove useful for the development of new diagnostic tests, studies on antigenic variation, and vaccine development in the global fight against SARS, as discussed above.

15 While the preferred embodiments of the invention have been described above, it will be recognized and understood that various modifications may be made therein, and the appended claims are intended to cover all such modifications which may fall within the spirit and scope of the invention.



Table 1: mAbs to the SARS HCoV Coronavirus

Clones	Class <sup>1</sup>	Neutralizing		Protein Target <sup>4</sup>	Conformational Requirement of Epitope in Immuno-dot blot <sup>5</sup>								IFA <sup>6</sup>	Epitope <sup>7</sup>
		Titre <sup>2</sup>	NCFA D <sup>3</sup>		N	H	D	HD	R	HR	A			
F26G1	G2a/k	0	0	Spike	+	+/-	+	-	+	+/-	-	+	L, E	
F26G2	G2a/k	0	0	U	nd	nd	nd	nd	nd	nd	nd	-	C	
F26G4	G2a/k	0	0	U	nd	nd	nd	nd	nd	nd	nd	--	C	
F26G5	G2a/k	0	0	Spike	+	+	+/-	+/-	+	+	+/-	+/-	L, E	
F26G6	G2b/k	0	0	Spike	+	+	+	+/-	+	+	+	++	L, E	
F26G8	G2a/k	0	0	Spike	+	+	+	+/-	+	+	+/-	-+	L, E	
F26G12	G2a/k	0	0	U	nd	nd	nd	nd	nd	nd	nd	-	C	
F26G13	G2b/k	0	0	U	nd	nd	nd	nd	nd	nd	nd	+/-	C, E	
F26G14	G2b/k	0	0	U	nd	nd	nd	nd	nd	nd	nd	+	C, E	
F26G16	G1/k	0	0	U	+	-	+	-	-	-	-	-	C	
F26G17	G2b/k	nd	0	U	nd	nd	nd	nd	nd	nd	nd	nd	C	
F26G3	G2a/k	>1/40	>1/20	U	+	-	+	-	-	-	-	+	C, E, P	
F26G7	G2b/k	>1/80	>1/20	U	+	-	+	-	+/-	-	-	+	C, E, P	
F26G9	G2a/k	>1/80	>1/20	U	+	-	+/-	-	-	-	-	+	C, E, P	
F26G10	G2a/k	>1/80	>1/20	U	+	-	+/-	-	-	-	-	++	C, E, P	
F26G18	G2b/k	nd	>1/20	Spike	+	+/-	+	-	+	+	-	nd	L, P	
F26G19	G2a/k	nd	>1/20	Spike	+	-	+	-	+/-	-	-	nd	L, P	

<sup>1</sup> Only IgG class antibodies were used for this study.

<sup>2</sup> Virus neutralization tests were performed in independent containment laboratories

5 (NML, National Microbiology Laboratory; NCFAD, National Centre for Foreign Animal Disease) laboratories independently.

<sup>3</sup> Only a single dilution of 1/20 was tested in microwell format.

<sup>4</sup> Protein specificity tests, shown here were determined by Western immunoblot with purified virus and infected cell lysate under denaturing conditions (Figure 1).

<sup>5</sup> Immunodot blot was performed using whole infected cell lysate separated into 6 different aliquots and then treated under various conditions described in methods. N,

5 native ; H, heat denatured, 95°C for 5 minutes ; D, SDS treated ( 2%) ; H+D, heated in the presence of SDS (2%); R, treated with reducing agent, betamercaptoethanol (5%) ; H+R, heated in the presence of reducing agent, betamercaptoethanol (5%); A, treated with heat, SDS (2%) and reducing agent betamercaptoethanol (5%).

<sup>6</sup> Immunofluorescence on whole cell slides infected with SARS coronavirus (see Fig. 2) ;  
10 ++ strong positive reaction; + positive reaction; +/- weak positive reaction; - negative reaction.

<sup>7</sup> Epitope properties described as follows: L, linear or continuous epitope; E, surface exposed; C, conformational epitope ; P, protective epitope in vitro; nd, not determined; neutralizing clones are embolded; U, Unknown

15

Bio-Activity	mAb	Western Reactivity	ELISA REACTIVITY				Meand
			Viral Lysate <sup>a</sup>	Denatured Lysate <sup>b</sup>	O.D. Reduction Fold <sup>c</sup>	Percent	
non-neutralizing	F26G2	-	0.743	0.424	1.7	43	51
	F26G4	-	0.751	0.363	2.1	52	
	F26G5	-	1.224	0.383	3.2	69	
	F26G12	-	0.533	0.338	2.9	37	
	F26G13	-	1.048	0.481	2.2	54	
	F26G14	-	1.448	0.633	2.3	56	
	F26G16	-	2.037	1.534	1.3	25	
	F26G17	-	1.986	0.560	3.5	73	
	F26G1	+	1.709	0.584	2.9	66	
	F26G6	+	1.600	0.600	2.7	62	
	F26G8	+	1.408	0.497	2.8	29	
	F26G15	+	1.134	0.604	1.9	47	
neutralizing	F26G3	-	1.253	0.276	4.5	78	78*
	F26G7	-	1.917	0.382	5.0	80	
	F26G9	-	1.345	0.278	4.8	79	
	F26G10	-	1.259	0.290	4.3	77	
	F26G18	+	1.807	0.501	3.6	72	
	F26G19	+	1.505	0.253	6.0	83	

<sup>a</sup>Native gradient purified virus coated at 32 ng/well total protein

<sup>b</sup>Denatured Virus was also coated at 32 ng/well after heating at 100°C for 10 minutes.

<sup>c</sup>Fold reduction in OD at 405nm

<sup>d</sup>Mean calculated based on groups of non-neutralizing or neutralizing monoclonal antibodies

\*p<0.001, students T-Test

This table depicts further ELISA characterisation of the nature of the epitopes.  
The neutralizing mAbs in general have a higher dependence on integrity of the native structure for binding.

5

10

15

CLAIMS

1. A SARS detecting monoclonal antibody selected from the group consisting of: F26G1, F26G2, F26G4, F26G5, F26G6, F26G8, F26G12, F26G13, F26G14, F26G16, F26G17, F26G3, F26G7, F26G9, F26G10, G26G18 and F26G19.

5 2. A SARS neutralizing monoclonal antibody selected from the group consisting of F26G3, F26G7, F26G9, F26G10, F26G18 and F26G19.

3. A kit comprising at least one monoclonal antibody selected from the group consisting of: F26G1, F26G2, F26G4, F26G5, F26G6, F26G8, F26G12, F26G13, F26G14, F26G16, F26G17, F26G3, F26G7, F26G9, F26G10, G26G18 and  
10 F26G19.

4. A pharmaceutical composition comprising a SARS neutralizing monoclonal antibody selected from the group consisting of F26G3, F26G7, F26G9, F26G10, F26G18, F26G19 and combinations thereof and a suitable excipient.

5. A method of preparing a chimeric antibody comprising:  
15 introducing an expression vector which comprises a nucleic acid encoding a constant region domain of a human light or heavy chain and a nucleic acid encoding a light chain variable region selected from the group consisting of G1-light (SEQ ID No.1); G3-light (SEQ ID No.2); G6-light (SEQ ID No.3); G7-light (SEQ ID No.4); G8-light (SEQ ID No.5); G10-light (SEQ ID No.6); G15-light (SEQ ID No.7) and  
20 G18-light(SEQ ID No.8) or a heavy chain variable region selected from the group consisting of G1-heavy (SEQ ID No.9); G3-heavy (SEQ ID No.10); G6-heavy (SEQ ID No.11); G15-heavy (SEQ ID No.12) and G18-heavy (SEQ ID No.13) into a suitable host cell;

growing the host cell under conditions promoting expression of the  
25 chimeric antibody; and

recovering the chimeric antibody.

6. A method of preparing a humanized antibody comprising:  
providing a nucleic acid comprising a light chain variable region selected from the group consisting of G1-light (SEQ ID No.1); G3-light (SEQ ID No.2); G6-light  
30 (SEQ ID No.3); G7-light (SEQ ID No.4); G8-light (SEQ ID No.5); G10-light (SEQ ID

No.6); G15-light (SEQ ID No.7) and G18-light(SEQ ID No.8) or a heavy chain variable region selected from the group consisting of G1-heavy (SEQ ID No.9); G3-heavy (SEQ ID No.10); G6-heavy (SEQ ID No.11); G15-heavy (SEQ ID No.12) and G18-heavy (SEQ ID No.13);

5            modifying said nucleic acid such that at least one but fewer than about 30 of the amino acid residues of said variable region has been changed and/or deleted without disrupting antigen binding;

                 introducing said nucleic acid into a suitable host cell;

                 growing the host cell under conditions promoting expression of the  
10    humanized antibody; and

                 recovering the humanized antibody.

7.     A pharmaceutical composition comprising a chimeric antibody of claim 5 and a suitable carrier.

8.     A pharmaceutical composition comprising a humanized antibody  
15    of claim 6 and a suitable carrier.

9.     A method of preparing a vaccine comprising:

                 recovering from a preparation of live, attenuated or recombinant SARS virus, antigens recognized by one or more monoclonal antibodies selected from the group consisting of F26G1, F26G2, F26G4, F26G5, F26G6, F26G8, F26G12,  
20    F26G13, F26G14, F26G16, F26G17, F26G3, F26G7, F26G9, F26G10, G26G18 and F26G19.

10.    A nucleic acid molecule encoding a peptide comprising a light chain variable region selected from the group consisting of G1-light (SEQ ID No.1); G3-light (SEQ ID No.2); G6-light (SEQ ID No.3); G7-light (SEQ ID No.4); G8-light  
25    (SEQ ID No.5); G10-light (SEQ ID No.6); G15-light (SEQ ID No.7) and G18-light(SEQ ID No.8) or a heavy chain variable region selected from the group consisting of G1-heavy (SEQ ID No.9); G3-heavy (SEQ ID No.10); G6-heavy (SEQ ID No.11); G15-heavy (SEQ ID No.12) and G18-heavy (SEQ ID No.13).

**ABSTRACT**

Monoclonal antibody reagents that recognize the SARS-coronavirus (SARS-HCoV) are needed urgently. In this report we describe the development and immunochemical characterisation of mAbs against the SARS-HCoV based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of seventeen mAbs. Five mAbs exhibited Western immunoblot reactivity with the denatured spike protein, of which two demonstrated the ability to neutralize SARS-HCoV in vitro. Another four Western immunoblot-negative mAbs also neutralize the virus. These antibodies will be useful for the development of diagnostic tests, pathogenicity and vaccine studies.




FIGURE 1




FIGURE 2






FIGURE 3




FIGURE 4





FIGURE 5

# SARS CoV mAb V<sub>L</sub> alignment




FIGURE 6A

# SARS CoV mAb V<sub>H</sub> alignment




FIGURE 6 B

SARS-specific monoclonal antibodies, Heavy chains (VH), amino acid sequences

**F26G3-VH**

EVRLQQSGPELVKPGASVKISCKTSGYTFTEYTMHWVKQSHGKNLEWIGGINPNNGGTTYN  
QKFKGKATLTVDKSSNTAYMELRSLTSEDSAVYYCSRGDYGTSYGYFDVWGAGTTVTVSSAKTTAPSVYPLA

**F26G7-VH**

VELLESGTVLARPGASVKMSCEASGYTFTTYWMHWIKQRPQGQLEWIGAIYPGNSDTTYNQKFKGKAKLTAVTSTS  
TAYMELSSLTNEEDSAVYYCTREGIPQLLRMTDYGWQGTSTVTVSSAKTTPPSV

**F26G9-VH**

VQLLESGTVLARPGASVKMSCKASGYSTSYWMHWVKQRPQGQLEWIGAIYPGNSDTSYNQKFKGKAKLTAVTSAS  
TAYMELSSLTNEEDSAVYYCTRSVYYGYGYFDVWGAGTTVTVSSAKTTPPSV

**F26G10-VH**

EVQLEESGTVLARPGASVKMSCKASGYSTSYWMHWVKQRPQGGLDWIGAIYPENS DTSYNQKFKGKAKLTAVTSA  
STAYMEHSSLTNEEDSAVYYCTRSVYYGYGYFDVWGAGTTVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGY  
FPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRVPTSQN

**F26G18-VH**

LVQLEESGTVLPRPGASVKMSCKASGYTFTSYWMHWVKQRPQGQLEWIGAIYPGNSDTNYNQKFKGRATLTAVTST  
STASMELSSLTNEEDSAVYYCTRDGYGSLYYYAMDFWGQGTSTVTVSSAKTTAPSVK

**F26G19-VH**

EVQLEESGTVLARPGASVKMSCKASGYTFTTYRMHWIKQRPQGQLEWIGAIYPGNSDTTYNQKFKDKAKLTAVTST  
SSAYMELSSLTNEEDSAVYFCTREGIPQLLRTLDYWGQGTSTVTVSSAKTTAPSVYPLA

**F26G1-VH**

EVQLEESGPGLVAPSQSLSTCTVSGFSLTNYDISWIRQPPGKGLEWLGI IWTGGGTSYNSAFMSRLSISKDNSKS  
QVFLKMNSLQTD DDTAIYYCVRDRVYYFPM DYWGQGTSTVTVSSAKTTAPSVYPLA

**F26G6-VH**

MEWSWVFLFLVATATDVHSQVQLQQPGAELVKPGASVKVSKASGYTFTNYWIHWVKQRPQGQLEWIGEINPGNGR  
TNYNGNFMNKATLTVDKSSNTAYMQLSSLTSEDSAVYH CARLDYWGQGTTLTVSSAKTTPPSV

**F26G8-VH**

VQLLESGAELVKPGASVKVSKASGYTFTSYWIHWVKQRPQGQLEWIGEINPSNGRTNYNGNFESKATLTVDKSSN  
TAYMHLSSLTYEDSAVYHCTRLDYWGQGTTLTVSSAKTTAPSVYPLA

Neutralizing mAbs are in bold text.

FIGURE 7

SARS-specific monoclonal antibodies, Light chains (VL), amino acid sequences

**F26G3-VL**

DILMTQSPTSFVSLGQRATISCRTSQSVSTSSYSYMHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGSDFT  
LNIHPVEEGDTATYYCQHSWEIPCAFGGGTKLEIKRADAAPTVS

**F26G7-VL**

ELVMTQSPSSLSASLGERVSLTCRASQEISGYLSWLQQKPDGTIKRLIYAASLTDSGVPKRFGSGSRSGSDYSLTIS  
SLESEDFADYYCLQYISYPWTFGGGKLEIKRADAAPTVS

**F26G9-VL**

DILMTQSHKCMSTSVGDRVSITCKASQDVSTAVVWYQQKPGQFPKLLIYWASTRHTGVPDRFTGSGSGTDYTLTIS  
SVQAEDLALYYCQQHYTTPYTFGGGKLEIKRADAAPTVS

**F26G10-VL**

DILMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDYTLTIS  
SVQAEDLALYYCQQHYSTPYTFGGGKLEIKRADAAPTVS

**F26G18-VL**

ELVMTQSPSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHAGVPSRFSGSGSGTDYSLTIS  
NLEQEDIATYFCQQGYTLPYTFGGGKLEIKRADAAPTVSKEGFQHTGGRY

**F26G19-VL**

DILMTQSPSSLSASLGERVSLTCRASQEISGYLSWLQEKPDGTIKRLIYAASLTDSGVPKRFGSGSRSGSDYSLTIS  
SLESEDFADYYCLQYVSYWTFGGGKLEIKRADAAPT

**F26G1-VL**

ELVMTQSPVSITASRGEKVTITCRASSISSNYLHWYQQKPGSSPKLLIYRTSILASGVLDTFSGSGSESSYTLTI  
SCMQDEVAATYYCQQGSSSPPHVRRGDQAGNKTG

**F26G6-VL**

ELVMTQSPASLSVATGKKVTIRCISSTDIDDDMNWYQQKAGKPPKLLISEGNIFSPGVPSRFSSSGNGTDFVFTVE  
NTLSEDVADNYCLQSDNMPFTFGSGTKLGIKRADAAPTVS

**F26G8-VL**

ELVMTQSPASLSVITGKKVTIRCISNTDIDDDLNWSQLKAGEPPKLLISEGNIFSPGVPSRFSSSGNGTDFVFTIE  
NTLSEDVANNYCFQSDNMPFTFGSGTKLEIKRADAAPTVS

Neutralizing mAbs are in **bold text**.

FIGURE 8

SARS-specific monoclonal antibodies, Heavy chains (VH), nucleotide sequences

**F26G3-VH**

ATGGAATGGAGCTGGGTCTTTCTCTTTCTCCTGTCAGGAACCTGCAGGTGTCTCTCTGAGGTCCGGCTGCAACAGT  
CTGGACCTGAACTGGTGAAGCCTGGGGCTTCAGTGAAGATATCCTGCAAGACTTCTGGATACACATTCAGTGAATA  
CACCATGCACTGGGTGAAGCAGAGCCATGGAAAGAACCCTTGAGTGGATTGGAGGTATTAATCCTAATAATGGTGGT  
ACTACCTACAACCAGAAGTTTAAGGGCAAGGCCACATTGACTGTAGACAAGTCCTCCAACACAGCCTACATGGAGC  
TCCGCAGCCTGACATCTGAGGATTCTGCAGTCTATTATTGTTCAAGAGGGGACTACGGTACTAGCTACGGGTACTT  
CGATGTCTGGGGCGCAGGGACCACGGTCACCGTCTCCTCAGCCAAAACAACAGCCCCATCGGTCTATCCACTGGCC  
A

**F26G7-VH**

GTGGAGCTGCTCGAGTCAGGGACTGTGCTGGCAAGGCCTGGGGCTTCAGTGAAGATGTCTGCGAGGCTTCTGGCT  
ACACCTTTACCACCTACTGGATGCACTGGATAAAACAGAGGCCTGGACAGGGTCTGGAATGGATTGGCGCTATTTA  
TCCAGGAAATAGTGATACTACCTACAACCAGAAGTTCAAGGGCAAGGCCAACTGACTGCAGTCACATCCACCAGC  
ACTGCCTACATGGAGCTCAGCAGCCTGACAAATGAGGACTCTGCGGTCTATTACTGTACAAGAGAGGGAATTCCCC  
AATTACTTCGGACTATGGACTACTGGGGTCAAGGGACCTCAGTCACCGTCTCCTCAGCCAAAACAACACCCCCATC  
GGTCA

**F26G9-VH**

GTCCAGCTGCTCGAGTCTGGGACTGTGCTGGCAAGGCCTGGGGCTTCCGTGAAGATGTCTGCAAGGCTTCTGGCT  
ACAGCTTTACCAGCTACTGGATGCACTGGGTAAAACAGAGGCCTGGACAGGGTCTAGAATGGATTGGTGCTATTTA  
TCCTGGAAATAGTGATACTAGCTACAACCAGAAGTTCAAGGGCAAGGCCAACTGACTGCAGTCACATCCGCCAGT  
ACTGCCTACATGGAGCTCAGCAGCCTGACAAATGAGGACTCTGCGGTCTATTACTGTACAAGATCCGTTTACTACG  
GCTACGGGTACTTCGATGTCTGGGGCGCAGGGACCACGGTCACCGTCTCCTCAGCCAAAACAACACCCCCATCGGT  
C

**F26G10-VH**

GAGGTGCAGCTGGAGGAGTCTGGGACTGTGCTGGCAAGGCCTGGGGCTTCCGTGAAGATGTCTGCAAGGCTTCTG  
GCTACAGCTTTACCAGCTACTGGATGCACTGGGTAAAACAGAGGCCTGGACAGGGTCTAGATTGGATTGGTGCTAT  
TTATCCTGAAAATAGTGATACTAGCTACAACCAGAAGTTCAAGGGCAAGGCCAACTGACTGCAGTCACATCCGCC  
AGCACTGCCTACATGGAGCACAGCAGCCTGACAAATGAGGACTCTGCGGTCTATTACTGTACAAGATCCGTTTACT  
ACGGCTACGGGTACTTCGATGTCTGGGGCGCAGGGACCACGGTCACCGTCTCCTCAGCCAAGACAACAGCCCCATC  
GGTCTATCCACTGGCCCCCTGTGTGTGGAGATACAACCTGGCTCCTCGGTGACTCTAGGATGCCTGGTCAAGGGTTAT  
TTCCCTGAGCCAGTGACCTTGACCTGGAACCTCTGGATCCCTGTCCAGTGGTGTGCACACCTTCCCAGCTGTCTG  
AGTCTGACCTCTACACCTCAGCAGCTCAGTGAACCTCGAGCACCTGGCCCAGCCAGTCCATCACCTGCAA  
TGTGGCCCCACCCGCAAGCAGCACCAAGGTGGACAAGAAAATTGAGCCCAGAGTGCCCACTAGTCAGAAC

**F26G18-VH**

TTGGTGCAGCTGGAGGAGTCTGGGACTGTGTTGCCAAGGCCTGGGGCTTCAGTGAAGATGTCTGCAAGGCTTCTG  
GCTACACCTTTACCAGCTACTGGATGCACTGGGTAAAACAGAGGCCTGGACAGGGTCTGGAATGGATTGGCGCTAT  
TTATCCTGGAAATAGTGATACTAATAACAACCAGAAGTTCAAGGGCAGGGCCACACTGACTGCAGTCACATCCACC  
AGCACTGCCTCCATGGAGCTCAGCAGCCTGACAAATGAGGACTCTGCGGTCTATTACTGTACAAGAGACGGCTATG  
GTAGCCTTTTACTATGCTATGGACTTCTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCAGCCAAAACAACAGC  
CCCATCGGTCAAGGGCGA

**F26G19-VH**

GAGGTGCAGCTGGAGGAGTCTGGGACTGTGCTGGCAAGGCCTGGGGCTTCAGTGAAGATGTCTGCAAGGCTTCTG  
GCTACACCTTTACCACCTACCGGATGCACTGGATAAAACAGAGGCCTGGACAGGGTCTGGAATGGATTGGCGCTAT  
TTATCCTGGAAATAGTGATACTACCTACAACCAGAAGTTCAAGGACAAGGCCAACTGACTGCAGTCACATCCACC  
AGCTCTGCCTACATGGAGCTCAGCAGCCTGACAAATGAGGACTCTGCGGTCTATTTCTGTACAAGAGAGGGAATTC  
CCCAATTACTTCGGACTTTGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCAGCCAAAACAACAGCCCC  
ATCGGTCTATCCACTGGCC

FIGURE 9-1.



F26G1-VH

TGAGGTGCAGCTGGAGGAGTCAGGACCTGGCCTGGTGGCGCCCTCACAGAGCCTGTCCATTACCTGCACTGTCTCT  
GGGTTCATTAAACGAACCTATGATATAAGCTGGATTTCGCCAGCCACCAGGAAAGGGTCTGGAGTGGCTTGGAATAA  
TATGGACTGGTGGAGGCACAAGTTATAATTCAGCTTTCATGTCCAGACTGAGCATCAGCAAGGACAACCTCCAAGAG  
CCAAGTTTTCTTAAAAATGAACAGTCTGCAAACTGATGACACAGCCATATATTACTGTGTAAGAGATAGGGTCTAC  
TACTTCCCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCAGCCAAAACAACAGCCCCATCGGTCT  
ATCCACTGGCCA

F26G6-VH

ATGGAATGGAGCTGGGTCTTTCTCTTTTTGGTAGCAACAGCTACAGATGTCCACTCCCAGGTCCAACCTGCAGCAGC  
CTGGGGCTGAACTGGTGAAGCCTGGGGCTTCAGTGAAAGTGTCTTGCAAGGCTTCTGGCTACACCTTCACCAACTA  
CTGGATACACTGGGTGAAGCAGAGGCCCTGGACAGGGCCTTGAGTGGATTGGAGAGATTAATCCTGGCAACGGTCGT  
ACTAACTATAATGGGAACCTTCATGAACAAGGCCACACTGACTGTAGACAAATCCTCCAACACAGCCTACATGCAAC  
TCAGCAGCCTGACATCTGAGGACTCTGCGGTCTATCACTGTGCAAGATTAGACTACTGGGGCCAAGGCACCACTCT  
CACAGTCTCCTCAGCCAAAACAACACCCCCATCGGTC

F26G8-VH

GTCCAGCTGCTCGAGTCTGGGGCTGAACTGGTGAAGCCTGGGGCTTCAGTGAAAGTGTCTTGCAAGGCTTCTGGCT  
ACACCTTCACCAGCTACTGGATACACTGGGTGAAGCAGAGGCCCTGGACAGGGCCTTGAGTGGATTGGAGAGATTAA  
TCCTAGCAACGGTCGTACTAACTATAATGGGAACCTTCGAGAGCAAGGCCACACTGACTGTAGACAAATCCTCCAAC  
ACAGCCTACATGCACCTCAGCAGCCTGACATATGAGGACTCTGCGGTCTATCACTGTACAAGATTAGACTACTGGG  
GCCAAGGCACCACTCTCACAGTCTCCTCAGCCAAAACAACAGCCCCATCGGTCTATCCACTGGCC

Neutralizing mAbs are in **bold text**.

FIGURE 9-2.

SARS-specific monoclonal antibodies, Light chains (VL), nucleotide sequences

**F26G3-VL**

GGGCCCAGCCGGCCGAGCTCGACATTCTGATGACCCAGTCTCCTACTTCCTTTGCTGTATCTCTGGGGCAGAGGGC  
CACCATCTCATGCAGGACCAGCCAAAGTGTCAGTACATCTAGCTATAGTTATATGCACTGGTACCAACAGAAACCA  
GGACAGCCACCCAAACTCCTCATCAAGTATGCATCCAACCTAGAATCTGGGGTCCCTGCCAGGTTCACTGGCAGTG  
GGTCTGGGTCACTTACCCTCAACATCCATCCTGTGGAGAGGGGGATACTGCAACATATTACTGTCAGCACAG  
TTGGGAGATTCCGTGCGCGTTTCGGAGGGGGGACCAAGCTGGAATAAAACGGGCTGATGCTGCACCAACTGTATCC

**F26G7-VL**

GTGCCAGATGTGAGCTCGTGATGACCCAGTCTCCATCCTCCTTATCTGCCTCTCTGGGAGAAAGAGTCAGTCTCAC  
TTGTCCGGCAAGTCAGGAAATTAGTGGTTATTTAAGCTGGCTTCAGCAGAAACCAGATGGAACATTAAACGCCTG  
ATCTACGCCGCATCCACTTTAGATTTCGGGTGTCCTCAAAAAGGTTCACTGGCAGTAGGTCTGGGTCACTATTCTC  
TCACCATCAGCAGCCTTGAAGTCTGAAGATTTTGCAGACTATTACTGTCTACAATATATTAGTTATCCGTGGACGTT  
CGGGGGAGGTACCAAGCTGGAATCAAACGGGCTGATGCTGCACCAACTGTATCC

**F26G9-VL**

GACATTCGTGATGACCCAGTCTCACAATGCATGTCCACATCAGTAGGAGACAGGGTCAGCATCACCTGCAAGGCCA  
GTCAGGATGTGAGTACTGCTGTAGTCTGGTATCAACAAAAACCAGGGCAATTTCTAACTACTGATTTACTGGGC  
ATCCACCCCGGCACACTGGAGTCCCTGATCGCTTCACAGGCAGTGGATCTGGGACAGATTATACTCTCACCATCAGC  
AGTGTGCAGGCTGAAGACCTGGCACTTTATTACTGTCAGCAACATTATACCACTCCGTACACGTTTCGGAGGGGGGA  
CCAAGCTGGAATAAAACGGGCTGATGCTGCACCAACTGTATCC

**F26G10-VL**

GGGCCCAGCCGGCCGAGCTCGACATTCTGATGACCCAGTCTCACAATTCATGTCCACATCAGTAGGAGACAGGGT  
CAGCATCACCTGCAAGGCCAGTCAGGATGTGAGTACTGCTGTAGCCTGGTATCAACAAAAACCAGGGCAATCTCCT  
AACTACTGATTTACTGGGCATCCACCCGGCACACTGGAGTCCCTGATCGCTTCACAGGCAGTGGATCTGGGACAG  
ATTATACTCTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCACTTTATTACTGTGAGCAACATTATAGCACTCC  
GTACACGTTTCGGAGGGGGGACCAAGCTGGAATAAAACGGGCTGATGCTGCACCAACTGTATCC

**F26G18-VL**

GAGCTCGTGATGACCCAGTCTCCATCCTCCTGTCTGCCTCTCTGGGAGACAGAGTCACCATCAGTTGCAGGGCAA  
GTCAGGACATTAGCAATTATTTAACTGGTATCAGCAGAAACCAGATGGAACGTGTTAACTCCTGATCTATTACAC  
ATCAAGATTACACGCAGGAGTCCCATCAAGGTTCACTGGCAGTGGGTCTGGAACAGATTATTCTCTCACCATTAGC  
AACCTGGAGCAAGAAGATATTGCCACTTACTTTTGCCAACAGGGTTATACGCTTCCGTACACGTTTCGGAGGGGGGA  
CCAAGCTGGAATAAAACGGGCTGATGCTGCACCAACTGTATCCAA

**F26G19-VL**

GACATTCGTGATGACCCAGTCTCCATCCTCCTTATCTGCCTCTCTGGGAGAAAGAGTCAGTCTCACTTGTCTGGGCAA  
GTCAGGAAATTAGTGGTTACTTAAGCTGGCTTCAGGAGAAACCAGATGGAACATTAAACGCCTGATCTACGCCGC  
TTCCACTTTAGATTCTGGTGTCCCAAAAAGGTTCACTGGCAGTAGGTCTGGGTCACTATTCTCTCACCATCAGC  
AGCCTTGAGTCTGAAGATTTTGCAGACTATTACTGTCTACAATATGTTAGTTATCCGTGGACGTTTCGGTGGAGGCA  
CCAAGCTGGAATCAAACGGGCTGATGCTGCACCAACTGTA

**F26G1-VL**

GTGCCAGATGTGAGCTCGTGATGACCCAGTCTCCAGTATCCATAACTGCATCTCGAGGGGAGAAGGTCACCATCAC  
CTGCCGTGCCAGCTCAAGTATAAGTTCCAATTACTTACACTGGTACCAGCAGAAGCCAGGATCCTCCCCTAACTT  
TTGATTTATAGGACATCCATCCTGGCATCTGGAGTCTGGACACCTTCAGTGGCAGTGGGTCTGAGAGCTCTTACA  
CTCTGACAATCAGCTGCATGCAGGACGAAGTTGCTGCCACTTACTATTGTGAGCAGGGGAGTAGTAGCCACCACA  
CGTTCGGAGGGGGGACCAAGCTGGAATAAAACGGGCTGATGCTGCACCAACTGTATCCA

Figure 10-1.

F26G6-VL

GTGCCAGATGTGAGCTCGTGATGACCCAGTCTCCAGCATCCCTGTCCGTGGCTACAGGAAAAAAGTCACCATCAG  
ATGCATAAGCAGCACTGACATTGATGATGATATGAACTGGTACCAGCAGAAGGCAGGAAAACCTCCTAAACTCCTT  
ATTCAGAAGGCAATATTTTTAGTCCTGGAGTCCCATCCCGATTCTCCAGCAGTGGCAATGGCACAGATTTGTTT  
TTACAGTTGAAAACACGCTCTCAGAAGATGTTGCAGATAACTACTGTTTGCAAAGTGATAACATGCCATTACGTT  
CGGCTCGGGGACAAAGTTGGGAATAAAACGGGCTGATGCTGCACCAACTGTATCC

F26G8-VL

GTGCCAGATGTGAGCTCGTGATGACCCAGTCTCCAGCATCCCTGTCCGTGATTACAGGAAAAAAGTCACCATCAG  
ATGCATAAGCAACACTGACATTGATGATGATTTGAACTGGTCCCAGCTGAAGGCAGGAGAACCTCCTAAACTCCTT  
ATTCAGAAGGCAATATTTTTAGTCCTGGAGTCCCATCCCGATTCTCCAGCAGTGGCAATGGCACAGATTTGTTT  
TTACAATTGAAAACACGCTCTCAGAAGATGTTGCAAATAACTACTGTTTCCAAAGTGATAACATGCCATTACGTT  
CGGCTCGGGGACAAAGTTGGAAATAAAACGGGCTGATGCTGCACCAACTGTATCC

Neutralizing mAbs are in **bold text**.

FIGURE 10-2